Xpert® MTB/RIF assay: Development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance

Future Microbiology

Volumn 6, Issue 9, 2011, Pages 1067-1082

  Lawn, Stephen D ^a,b   Nicol, Mark P ^c,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

accuracy; biosafety; diagnosis; GeneXpert; nucleic acid amplification test; resistance; rifampicin; rpoB; tuberculosis; Xpert

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; BIOSAFETY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; EVALUATION; EXTRAPULMONARY TUBERCULOSIS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LABORATORY DIAGNOSIS; MOLECULAR BEACON; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; RIFAMPICIN RESISTANCE; SPUTUM ANALYSIS; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

CLINICAL TRIALS AS TOPIC; DIAGNOSTIC TEST APPROVAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 80053506597     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.84     Document Type: Review

References (53)

1. Lawn SD, Zumla AI. Tuberculosis. Lancet 378, 57-72 (2011).
2. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375, 1830-1843 (2010).
3. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin. Chest Med. 30, 701-716 (2009).
4. Small PM, Pai M. Tuberculosis diagnosis -time for a game change. N. Engl. J. Med. 363, 1070-1071 (2010).
5. Piatek AS, Tyagi S, Pol AC, et al. Molecular beacon sequence analysis for detecting drug resistance in mycobacterium tuberculosis. Nat. Biotechnol. 16, 359-363 (1998).
6. Piatek AS, Telenti A, Murray MR, et al. Genotypic analysis of mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob. Agents Chemother. 44, 103-110 (2000). (Pubitemid 30010679)
7. El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in mycobacterium tuberculosis in a single tube with molecular beacons. J. Clin. Microbiol. 39, 4131-4137 (2001). (Pubitemid 33029793)
8. Helb D, Jones M, Story E, et al. Rapid detection of mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48, 229-237 (2010).
9. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert(R) MTB/RIF assay. J. Clin. Microbiol. 48, 249-251 (2010).
10. Banada PP, Sivasubramani SK, Blakemore R et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J. Clin. Microbiol. 48, 3551-3557 (2010).
11. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363, 1005-1015 (2010)
12. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377, 1495-1505 (2011)
13. Greco S, Girardi E, Navarra A, Saltini C. Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax 61, 783-790 (2006). (Pubitemid 44369403)
14. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE 3, e1536, (2008).
15. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM Jr. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect. Dis. 4, 6 (2004).
16. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM Jr. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect. Dis. 3, 633-643 (2003). (Pubitemid 37210227)
17. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr. Opin. HIV AIDS 4, 325-333 (2009).
18. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8, 496-514 (1995).
19. Sreevatsan S, Pan X, Stockbauer KE, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl Acad. Sci. USA 94, 9869-9874 (1997). (Pubitemid 27408157)
20. Tyagi S, Kramer FR. Molecular beacons: probes that fluoresce upon hybridization. Nat. Biotechnol. 14, 303-308 (1996).
21. Tyagi S, Bratu DP, Kramer FR. Multicolor molecular beacons for allele discrimination. Nat. Biotechnol. 16, 49-53 (1998). (Pubitemid 28035948)
22. Ulrich MP, Christensen DR, Coyne SR, et al. Evaluation of the cepheid GeneXpert system for detecting bacillus anthracis. J. Appl. Microbiol. 100, 1011-1016 (2006).
23. No authors listed. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am. J. Respir. Crit. Care Med. 161, 1376-1395 (2000).
24. Marlowe EM, Novak-Weekley SM, Cumpio J et al. Evaluation of the cepheid Xpert MTB/ RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J. Clin. Microbiol. 49, 1621-1623 (2011).
25. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaitre N. Comparison of the Xpert MTB/ RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens J. Clin. Microbiol. 49, 1772-1776 (2011).
26. Moure R, Munoz L, Torres M, Santin M, Martin R, Alcaide F. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J. Clin. Microbiol. 49, 1137-1139 (2011).
27. Bowles EC, Freyee B, van Ingen J, Mulder B, Boeree MJ, van SD. Xpert MTB/RIF(R), a novel automated polymerase chain reactionbased tool for the diagnosis of tuberculosis. Int. J. Tuberc. Lung Dis. 15, 988-989 (2011).
28. Nicol MP, Workman L, Isaacs W, et al. A descriptive study of the accuracy of the Xpert MTB/RIF test for diagnosis of pulmonary tuberculosis in hospitalized children in a high HIV prevalence area. Lancet Infect. Dis. doi:10.1016/S1473-3099(11)70167-0 (2011) (Epub ahead of print).
29. Hatherill M, Hanslo M, Hawkridge T, et al. Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa. Bull. World Health Organ. 88, 312-320 (2010).
30. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert(R) MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am. J. Respir. Crit. Care Med. (2011).
31. Hillemann D, Rusch-Gerdes S, Boehme C, Richter E. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J. Clin. Microbiol. 49, 1202-1205 (2011).
32. Causse M, Ruiz P, Juan Bautista GA, Casal M. Comparison of two molecular methods for the rapid diagnosis of extrapulmonary tuberculosis. J. Clin. Microbiol. 49(8), 3065-3067 (2011).
33. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF, a new pillar in the diagnosis of extrapulmonary tuberculosis? J. Clin. Microbiol. 49(7), 2540-2545 (2011).
34. Van Rie A, Menezes C, Scott L, et al. High yield, sensitivity and specificity of Xpert MTB/ RIF for M. tuberculosis detection in fine needle aspirates from HIV-infected TB suspects. Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. (2011) (Abstract #879).
35. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy. A prospective study. PLoS Med. 8(7), e1001067 (2011)
36. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J. Infect. Dis. (2011) (In Press).
37. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin. Infect. Dis. 51, 823-829 (2010).
38. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 23, 1875-1880 (2009).
39. Lawn SD, Wood R. Tuberculosis screening in patients starting antiretroviral therapy in sub-Saharan Africa: stretching diagnostics to the limits. Clin. Infect. Dis. 52, 276-277 (2011).
40. Cox HS, McDermid C, Azevedo V, et al. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS ONE 5, e13901 (2010).
41. Lonnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 375, 1814-1829 (2010).
42. Abu-Raddad LJ, Sabatelli L, Achterberg JT et al. Epidemiological benefits of moreeffective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA 106, 13980-13985 (2009).
43. Ioannidis P, Papaventsis D, Karabela S, et al. Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with high clinical suspicion of TB and smear negative microscopy. J. Clin. Microbiol. 49(8), 3068-3070 (2011).
44. Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial (JCM00138-11). J. Clin. Microbiol. 49(8), 2827-2831 (2011).
45. WHO. Global tuberculosis control 2010. Geneva: WHO, 2010 www.who.int/tb/publications/global-report/2010/en/index.html
46. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB). 2010 global report on surveillance and response. WHO, Geneva, 2010. WHO/HTM/ TB/2010.3 http://whqlibdoc.who.int/ publications/2010/9789241599191-eng.pdf (Accessed 18th August 2010)
47. WHO. Molecular line probe assays for rapid screening of patients at risk of multidrugresistant tuberculosis (MDR-TB). Policy statement June 2008 www.who.int/entity/tb/dots/laboratory/ lpa-policy.pdf
48. Cepheid Systems www.cepheid.com/systems-and-software/ systems-overview
49. Rachow A, Mtafya B, Rojas-Ponce G, et al. Detection of Mycobacterium tuberculosis using the Cepheid Xpert MTB/RIF assay -a clinical validation study from Tanzania. 41st Union World Conferenec on Lung Health. Berlin, Germany, 11-15 November 2010 Abstract session 01 http://uwclh.conference2web.com/ content/667 (Accessed 19th April 2011)
50. Nicol M. Algorithms for referral to rapid diagnostics for MDR-TB: preliminary outcomes. 41st Union World Conference on Lung Health. International Union Against Tuberculosis and Lung Disease. Berlin, Germany, November 2010. Session #10 http://uwclh.conference2web.com/ content/227 (Accessed 2nd February 2011)
51. WHO. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational How to; practical considerations. WHO, Geneva. 2011 http://whqlibdoc.who.int/ publications/2011/9789241501569-eng.pdf (Accessed 28th June 2011)
52. WHO. Tuberculosis diagnostics automated DNA test. WHO endorsement and recommendations. World Health Organization, Geneva, 2010 www.who.int/tb/ features-archive/xpert-factsheet.pdf
53. WHO. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. World Health Organization, Geneva, December 2010 www.who.int/tb/ laboratory/roadmap-xpert-mtb-rif-rev23dec2010.pdf (Accessed 8th December 2010)